- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT06769048
Une étude pour tester différentes doses de BI 1584862 chez des personnes atteintes d'une forme distincte de dégénérescence maculaire liée à l'âge (DMLA) appelée atrophie géographique
JADE : Essai de phase II chez des patients atteints d'atrophie géographique : une étude de recherche de dose randomisée, en double insu, contrôlée par placebo pour évaluer l'efficacité et l'innocuité du BI 1584862
This study is open to adults aged 50 years and older with geographic atrophy that was diagnosed by imaging of the retina. The purpose of this study is to find out whether a medicine called BI 1584862 improves the eyes in people with geographic atrophy and to find the most suitable dose.
This study has 4 treatment groups. Participants are put into groups randomly, which means by chance. Initially participants can join a BI 1584862 and a placebo group; then more participants are put randomly in 2 additional BI 1584862 groups and a placebo group.
Participants are in the study for 1 year. During this time, they visit the study site 13 times. At the visits, doctors check the severity of participants' eye disease and collect information on any health problems. They take detailed pictures of the back of the eye, the retina, with imaging methods called fundus autofluorescence (FAF), near-infrared reflectance (NIR), and optical coherence tomography (OCT). They measure areas of the retina that appear healthy (bright) or start to waste away (dark, atrophy). The changes over time are then compared between the treatment groups.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Réel)
Phase
- Phase 2
Contacts et emplacements
Lieux d'étude
-
-
-
Arecibo, Porto Rico, 00612
- Emanuelli Research & Development Center
-
-
-
-
Arizona
-
Gilbert, Arizona, États-Unis, 85297
- Associated Retina Consultants
-
Phoenix, Arizona, États-Unis, 85020
- Associated Retina Consultants, Ltd.
-
Phoenix, Arizona, États-Unis, 85050
- Cameron Ria, LLC
-
Scottsdale, Arizona, États-Unis, 85255
- Retina Macula Institute of Arizona
-
-
California
-
Beverly Hills, California, États-Unis, 90211
- Retina-Vitreous Associates Medical Group
-
Glendale, California, États-Unis, 91204
- Global Research Management
-
Huntington Beach, California, États-Unis, 92647
- Retina Associates of Southern California
-
Modesto, California, États-Unis, 95356
- Retinal Consultants Medical Group, Inc
-
Mountain View, California, États-Unis, 94040
- Northern California Retina Vitreous Associates MedicalGroup, Inc.
-
Newport Beach, California, États-Unis, 92663
- Eye Research Foundation
-
Poway, California, États-Unis, 92064
- Retina Consultants of San Diego
-
Sacramento, California, États-Unis, 95825
- Retinal Consultants Medical Group
-
Walnut Creek, California, États-Unis, 94598
- Bay Area Retina Associates - Walnut Creek
-
-
Colorado
-
Denver, Colorado, États-Unis, 80222
- Retina Specialists of Colorado Research, LLC
-
-
Connecticut
-
Greenwich, Connecticut, États-Unis, 06830
- Coastal Eye Surgeons
-
-
Florida
-
Gainesville, Florida, États-Unis, 32605
- Vitreo Retinal Associates - Gainesville
-
Miami, Florida, États-Unis, 33143
- MedEye Associates
-
Pinellas Park, Florida, États-Unis, 33782
- Eye Associates of Pinellas
-
Stuart, Florida, États-Unis, 34994
- East Florida Eye Institute
-
Winter Haven, Florida, États-Unis, 33880
- Center for Retina and Macular Disease
-
-
Georgia
-
Augusta, Georgia, États-Unis, 30909
- Southeast Retina Center, PC
-
-
Illinois
-
Oak Park, Illinois, États-Unis, 60304
- Illinois Retina Associates - Oak Park
-
-
Kentucky
-
Louisville, Kentucky, États-Unis, 40206
- The Eye Care Institute
-
-
Maryland
-
Hagerstown, Maryland, États-Unis, 21740
- Cumberland Valley Retina Consultants
-
-
Massachusetts
-
Boston, Massachusetts, États-Unis, 02114
- Ophthalmic Consultants of Boston
-
-
Missouri
-
Columbia, Missouri, États-Unis, 65212
- University of Missouri Health System
-
-
New Jersey
-
Teaneck, New Jersey, États-Unis, 07666
- NJRetina
-
-
Oregon
-
Eugene, Oregon, États-Unis, 97401
- Verum Research, LLC
-
Portland, Oregon, États-Unis, 97221
- Retina Northwest
-
Portland, Oregon, États-Unis, 97225
- EyeHealth Northwest
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, États-Unis, 19107
- Mid Atlantic Retina - Wills Eye Hospital
-
-
South Carolina
-
Charleston, South Carolina, États-Unis, 29414
- Charleston Neuroscience Institute - Charleston
-
-
Tennessee
-
Nashville, Tennessee, États-Unis, 37203
- Tennessee Retina
-
-
Texas
-
Austin, Texas, États-Unis, 78750
- Austin Clinical Research, LLC
-
Beaumont, Texas, États-Unis, 77707
- Retina Consultants of Texas - Beaumont
-
Dallas, Texas, États-Unis, 75231
- Retina Foundation of the Southwest
-
Plano, Texas, États-Unis, 75024
- Red River Research Partners, LLC - Plano
-
San Antonio, Texas, États-Unis, 78240
- Retinal Consultants of San Antonio
-
Schertz, Texas, États-Unis, 78154
- Retina Consultants of Texas - Schertz
-
The Woodlands, Texas, États-Unis, 77384
- Retina Consultants of Texas-The Woodlands-67575
-
-
Virginia
-
Falls Church, Virginia, États-Unis, 22042
- Emerson Clinical Research Institute
-
Lynchburg, Virginia, États-Unis, 24502
- Piedmont Eye Center
-
-
Washington
-
Bellevue, Washington, États-Unis, 98004
- Pacific Northwest Retina
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion criteria:
-
Men and women with at least 1 eye with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) determined by fundus autofluorescence (FAF). The total size of all GA lesions in the study eye (as determined by the independent central reading center (CRC)) must be ≥1.25 mm^2 and ≤12.0 mm^2:
- If multiple lesions are present in the study eye, at least 1 lesion must have an area of ≥0.5 mm^2
- At least 1 GA lesion must be at least in part within a 1500 μm radius ring centered on the fovea
- The foveal center point must not be involved in any atrophic lesion
- Lesion(s) must reside completely within the FAF image
-
Best corrected visual acuity (BCVA) score of ≥50 letters in the study eye using the early treatment diabetic retinopathy study (ETDRS) chart (approximately equivalent to ≥20/100 on the Snellen chart).
-
Hyperautofluorescence of any pattern, as assessed by the CRC, must be present in the junctional zone of GA in the study eye.
-
Age ≥50 years.
-
Men must be willing and able to use contraception (condom, abstinence) to prevent pregnancy and/or exposure of an existing embryo or fetus to the investigational product. A female participant is eligible if she is not a woman of childbearing potential.
-
Signed informed consent consistent with International Conference of Harmonization-Good Clinical Practice (ICH GCP) guidelines and local legislation
Exclusion criteria:
-
Any history of, or evidence of, exudative age-related macular degeneration (eAMD) in the study eye.
-
Previously received treatment for GA in the study eye within 4 months or 5 half-lives, prior to baseline, whichever is longer.
-
Previously received an investigational medication (oral or intravitreal) for GA within 4 months or 5 half-lives prior to baseline, whichever is longer.
-
Additional eye disease in the study eye that could compromise BCVA or significantly impact retinal morphology:
- uncontrolled glaucoma, defined as a disk-to-cup ratio >0.8 or ocular hypertension with intra ocular pressure (IOP) >24 mmHg at screening visit, or use of >2 active IOP-lowering agents in the study eye
- clinically significant diabetic retinopathy or maculopathy in the opinion of the investigator
- history of high myopia, i.e. spherical equivalent of ≥8 diopters or axial length ≥27.2 mm. Note: if subject had prior cataract or refractive surgery, spherical equivalent should be evaluated with pre-operative refraction. If axial length measurement is not available in medical records and cannot be obtained at screening visit, assessment of high myopia can be made by investigator on clinical examination.
- anterior segment and vitreous abnormalities that would preclude adequate observation with SD-OCT in the opinion of the investigator
- other ocular conditions at the discretion of the investigator that might interfere with the outcome of the trial
-
Significant disease or other medical conditions (as determined by medical history, examination, and clinical investigations at screening) that may, in the opinion of the investigator result in any of the following:
- put the participant at risk because of participation in the study
- influence the results of the study
- cause concern regarding the participant's ability to comply with the protocol requirements or complete the trial as scheduled (e.g. chronic alcohol or drug abuse or any other condition that, in the investigator's opinion, makes the participant an unreliable trial participant)
-
Known hypersensitivity to any of the ingredients used in the investigational medicinal product (IMP) formulation, or any of the medications used.
-
Active intraocular inflammation in the study eye.
-
Active infectious conjunctivitis in either eye. Further exclusion criteria apply.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Quadruple
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Comparateur placebo: BI 1584862 correspondant au placebo
|
Placebo-matching BI 1584862 |
|
Expérimental: BI 1584862 dose 1
|
BI 1584862 |
|
Expérimental: BI 1584862 dose 2
|
BI 1584862 |
|
Expérimental: BI 1584862 dose 3
|
BI 1584862 |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Slope of change from baseline in square root transformed geographic atrophy (GA) area as measured by fundus autofluorescence (FAF) over a treatment period of up to 50 weeks (expressed in mm/year) in the study eye
Délai: Up to week 50.
|
mm is millimeters. |
Up to week 50.
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Apparition de TEAES depuis l'administration du médicament jusqu'à la semaine 52
Délai: Jusqu'à la semaine 52.
|
Jusqu'à la semaine 52.
|
|
|
Modification par rapport à la valeur initiale de l'atténuation partielle en pourcentage de la zone ellipsoïde (EZ) au niveau de la zone maculaire d'épaisseur <20 microgrammes (μm) jusqu'à la semaine 50, évaluée par tomographie par cohérence optique volumétrique (OCT) dans l'œil étudié
Délai: Jusqu'à la semaine 50.
|
Jusqu'à la semaine 50.
|
|
|
Changement par rapport à la valeur initiale de la zone d'atrophie géographique (AG) transformée en racine carrée, telle que mesurée par autofluorescence du fond d'œil (FAF) à la semaine 50 (exprimée en mm) dans l'œil étudié
Délai: Au départ et à la semaine 50.
|
Au départ et à la semaine 50.
|
|
|
Key secondary endpoint: Change from baseline in total attenuation as a percentage of the EZ at the macular area with a thickness of 0 μm up to week 50 assessed by volumetric OCT and EZ mapping in the study eye
Délai: Up to week 50.
|
EZ stands for ellipsoid zone. OCT stands for optical coherence tomography. |
Up to week 50.
|
|
Key secondary endpoint: Slope of change from baseline in square root transformed GA area as measured by OCT over a trial period of up to 50 weeks (expressed in mm/year) in the study eye
Délai: Up to week 50.
|
GA stands for geographic atrophy. OCT stands for optical coherence tomography. mm is millimeters. |
Up to week 50.
|
|
Occurrence of BCVA letter loss of ≥15 from baseline in the study eye as measured by standardized ETDRS chart for at least 2 consecutive visits between baseline and up to Week 50
Délai: Up to week 50.
|
ETDRS is early treatment diabetic retinopathy study. |
Up to week 50.
|
|
Change from baseline in best-corrected low luminance visual deficit (LLVD) score as measured in letters by ETDRS chart under low-luminance conditions at Week 50 in the study eye
Délai: At baseline and at week 50.
|
ETDRS is early treatment diabetic retinopathy study. |
At baseline and at week 50.
|
Collaborateurs et enquêteurs
Parrainer
Publications et liens utiles
Liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 1484-0005
- U1111-1309-9115 (Identificateur de registre: WHO International Clinical Trials Registry Platform (ICTRP))
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Once the criteria in section "Time Frame" are fulfilled, researchers can use the following link https://www.mystudywindow.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed "Document Sharing Agreement".
Furthermore, researchers can request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website.
Délai de partage IPD
One year after the approval has been granted by major Regulatory Authorities and after the primary manuscript has been accepted for publication, or after termination of the development program.
Critères d'accès au partage IPD
For study documents - upon signing of a 'Document Sharing Agreement'.
For study data - 1. after the submission and approval of the research proposal (checks will be performed by the sponsor and/or the independent review panel, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a legal agreement.
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .